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Chronic kidney disease · Bone quality · Bone mineral 
density
Abstract
Background: There is ample evidence that patients with 
CKD have an increased risk of osteoporotic fractures. Bone 
fragility is not only influenced by low bone volume and mass 
but also by poor microarchitecture and tissue quality. More 
emphasis has been given to the quantitative rather than 
qualitative assessment of bone health, both in general pop-
ulation and CKD patients. Although bone mineral density 
(BMD) is a very useful clinical tool in assessing bone strength, 
it may underestimate the fracture risk in CKD patients. Serum 
and urinary bone biomarkers have been found to be reflec-
tive of bone activities and predictive of fractures indepen-
dently of BMD in CKD patients. Bone quality and fracture risk 
in CKD patients can be better assessed by utilizing new tech-
nologies such as trabecular bone score and high-resolution 
imaging studies. Additionally, invasive assessments such as 
bone histology and micro-indentation are useful counter-
parts in the evaluation of bone quality. Summary: A precise 
diagnosis of the underlying skeletal abnormalities in CKD pa-
tients is crucial to prevent further bone loss and fractures. We 
must consider bone quantity and quality abnormalities for 
management of CKD patients. Here in this part I, we are fo-
cusing on advances in bone quality diagnostics that are ex-
pected to help in proper understanding of the bone health 
in CKD patients. Key Messages: Assessment of bone quality 
and quantity in CKD patients is essential. Both noninvasive 
and invasive techniques for the assessment of bone quality 
are available. © 2021 The Author(s)
Published by S. Karger AG, Basel
Introduction
CKD affects 8–10% of the population [1]. The fracture 
risk in CKD patients increases with worsening kidney 
function, suggesting specific CKD-related causes. Bone 
disease is a major complication of CKD and is a manifes-
tation of CKD-mineral bone disorder. Renal osteodystro-
phy (ROD) is an alteration of bone morphology in pa-
tients with CKD and is a measure of the skeletal compo-
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nent of the systemic disorder of CKD-mineral bone 
disorder, which is quantifiable by histomorphometry [2].
Because of the ease of use and widespread availability 
of dual-energy X-ray absorptiometry (DEXA), opera-
tionally the World Health Organization (WHO) defined 
osteoporosis as a reduction in bone mineral density 
(BMD) t scores of ≥2.5 standard deviations from the 
mean value in young adults [3]. This definition is now 
routinely used worldwide in clinical practice for the diag-
nosis of osteoporosis. Fractures may also occur, however, 
with low-energy trauma in non-osteoporotic patients, as 
classified based on their BMD t scores [4–6]. In 2000, the 
NIH defined osteoporosis as “a skeletal disorder charac-
terized by compromised bone strength predisposing to an 
increased risk of fracture.” Bone strength reflects the in-
tegration of 2 main components: bone quantity and bone 
quality [7].
Thus, bone quantity (assessed by DEXA to give 2-di-
mensional areal BMD or with quantified 3-dimensional 
quantitative computed tomography [QCT] for volume) 
is only one component. Bone quality is a second major 
component and includes bone remodeling abnormalities, 
collagen cross-linking, and mineralization properties. 
Remodeling abnormalities are generally evaluated with 
bone biopsy and dynamic histomorphometry (tetracy-
cline labeling), and such abnormalities are nearly univer-
sal in patients with CKD [8].
WHO developed a Fracture Risk Assessment Tool 
(FRAX) in the general population [9]. The addition of 
BMD to the FRAX score improves the prediction of frac-
ture risk; however, bone quality is not included in this 
tool. There is an option to say yes or no to secondary os-
teoporosis; however, this does not include CKD. It might 
be useful to add bone quality measurement in the general 
population and the CKD as a secondary cause of osteopo-
rosis to improve fracture risk prediction.
Bone quality can be evaluated by studying bone vol-
ume, microarchitecture, material properties, and micro-
damage. All these factors can be assessed at macro, micro, 
and nano hierarchical levels by various diagnostic mo-
dalities [10]. Of the spectrum of methods available to as-
sess bone quality from several different perspectives, we 
describe the clinically relevant ones. The pros and cons of 
each method of bone quality assessment in CKD patients 
are included in Figure 1.
PTH & bone
turnover markers
•   Noninvasive
•   Aids in prediction of bone turnover
•   Because of renal clearance, osteocalcin, P1NP and CTX has limited use in CKD
BMD- DEXA •   Widely available and noninvasive
•   Low radiation exposure & used in FRAX
•   Correlates with cortical porosity in CKD
•   Unable to assess type of ROD
•   Assess areal density only
•   Cannot distinguish cortical from trabecular bone
Trabecular bone
score
•   Noninvasive, Independent fracture predictor
•   Can be applied retrospectively to DEXA
•   No extra radiation, time and expense
•   Cannot detect type of ROD
•   Image noise degrades resolution
•   Variability among various software's
Quantitative
ultrasound
•   Non invasive with no radiation exposure
•   Portable
•   Correlates with BMD-DEXA
•   Only at distal extremity sites
•   Inter-observer variability
•   Lack of fracture predictability data in CKD
QCT •   3D volumetric assessment of spine and femur
•   Not affected by extra skeletal calcification
•   High radiation exposure
•   Expensive and cannot detect type of ROD
HRpQCT •   Assesses microarchitecture noninvasively
•   Good cortical and trabecular differentiation
•   Correlates with bone histopathology
•   Expensive and not widely available
•   Investigational tool only
•   Only distal extremity site (tibia and radius)
HR-MRI •   Non-ionizing
•   Can image central bones (hip)
•   Expensive
•   Not widely available
Finite element
analysis (FEA)
•   Improves bone quality assessment by CT and MRI
•   Aids CT and MRI in evaluating mechanical properties & fracture prediction
•   Lack of standardization
•   Various loading conditions can affect the estimation of strength
Reference point
indentation
•   Good in-vivo measure of bone stiffness & quality
•   Correlates well with fracture risk
•   Correlates with BMD and TBS in CKD
•   Invasive and can cause local complications
•   Does not represent whole bone strength
•   Does not detect type of ROD
Bone biopsy •   Gold standard as it directly assesses bone turnover, mineralization and
     volume
•   Assess bone marrow, can detect heavy metals and micro-cracks
•   Invasive and cannot detect whole bone strength
•   Not widely available and needs expertise
FTIR &
nano-indentation
•   Provides data on bone material properties
•   Adds additional information about bone quality
•   Limited availability and needs bone tissue
•   Only provides relative measures of mineral/matrix etc
PROS CONS
Fig. 1. The pros and cons of each method of bone quality assessment in CKD patients.




PTH and Bone Turnover Markers
Bone turnover markers (BTMs) give an idea of the 
bone resorption and bone formation rate. They provide 
an integrated dynamic assessment of skeletal metabolism 
and facilitate ROD management [11]. Bone formation 
markers including bone-specific alkaline phosphatase 
(BSAP), osteocalcin, and procollagen type-1 N-terminal 
propeptide (P1NP) are markers of osteoblast function. 
Bone resorption markers such as tartrate-resistant acid 
phosphatase 5b (Trap-5b) and C-terminal telopeptides of 
type I collagen (CTX) are markers of osteoclast function. 
BSAP and Trap-5b are not cleared by the kidneys, hence 
used in CKD patients. On the other hand, osteocalcin, 
P1NP monomer, and CTX are cleared by the kidneys, and 
their usefulness in CKD patients remains unclear. Serum 
intact PTH (iPTH) and BSAP are the most commonly 
used turnover markers to discriminate renal bone dis-
ease. In dialysis patients, Sprague et al. [12] reported that 
iPTH and whole PTH (wPTH) level of <2 times the upper 
limit of normal had a sensitivity of 65 and 74% and a spec-
ificity of 67 and 57%, respectively, for low-turnover bone 
disease (LTBD). iPTH and wPTH of >9 times the upper 
limit of normal showed a sensitivity of 37 and 31% and a 
specificity of 86 and 88%, respectively, for high-turnover 
bone disease (HTBD) [12]. Monier-Faugere et al. [13] 
studied PTH-(1–84)/-(7–84) ratio. They found that a ra-
tio of >1 had 100% sensitivity for HTBD, and a ratio of <1 
had 100% sensitivity for LTBD. Ureña et al. [14] demon-
strated that BSAP >20 and <20 ng/mL has 100% sensitiv-
ity and specificity for HTBD and LTBD, respectively, in 
hemodialysis (HD) patients.
BTMs also assist in bone loss and fracture risk predic-
tion in CKD patients. In a cross-sectional study, Nickolas 
et al. reported that osteocalcin, P1NP, and Trap-5b dis-
criminated fracture status in pre-dialysis CKD patients 
independent of BMD. They also noted a strong relation-
ship between iPTH and BTMs, trabecular volumetric 
BMD, and microarchitecture compared to cortical volu-
metric BMD or thickness. They explained this by the ef-
fect of hyperparathyroidism preferentially on the meta-
bolically active trabecular bone [15]. However, the same 
group, in a more recent longitudinal study of CKD pa-
tients (including dialysis), showed that hyperparathy-
roidism and high BTMs were associated with decreased 
cortical density and thickness but not with trabecular 
changes [16].
Laowalert et al. [17] in a recent study found that serum 
iPTH >484.5 or TRAP-5b >1.9 pg/mL has 92% sensitivity 
and 50% specificity for prediction of HTBD in Asian HD 
patients. The sensitivity goes down to 58% but the speci-
ficity goes up to 100% when they combined both. Limori 
et al. [18] found that iPTH levels of <150 or >300 pg/mL 
along with higher BSAP levels (>19.9 μg/L) were associ-
ated with a higher fracture risk in ESRD. Perrin et al. [19] 
reported that iPTH levels ≥130 pg/mL at 3 months post-
transplantation predicted incident fractures in kidney 
transplant recipients.
In our laboratory, we previously studied FGF23 as a 
potential bone marker in adult dialysis patients. FGF23 
correlated well with mineralization parameters. Patients 
with very high FGF23 levels had normal mineralization 
lag time [20]. Activin A is considered a regulator of bone 
turnover and is one of the markers of increased osteoclast 
activity [21]. Our group previously reported that serum 
activin A is one of the first biomarkers that goes up in 
ROD and correlates well with bone turnover [22].
Sclerostin levels increase with CKD progression, and 
its serum levels are associated with cardiovascular events 
[23, 24]. Osteocytes are the main source of sclerostin, 
though kidney, liver, and vascular wall can secrete it too 
[25]. Mare et al. [26] reported a negative correlation be-
tween skeletal and circulating sclerostin levels with histo-
morphometric measures of bone turnover. Cejka et al. 
[27] previously described a promising role of serum 
sclerostin level in addition to iPTH in the diagnosis of 
HTBD in dialysis patients. Furthermore, Malluche et al. 
[28] found that baseline serum sclerostin and Trap-5b 
levels predicted bone loss. Circulating sclerostin is dialyz-
able, so timing of blood draw is crucial while interpreting 
the results in dialysis patients [29]. Furthermore, in pa-
tients undergoing peritoneal dialysis, sclerostin is present 
in very high concentrations in the peritoneal fluid [30]. 
Thus, the utility of serum sclerostin as a BTM in CKD, 
especially in HD and peritoneal dialysis patients, is yet to 
be determined.
DEXA Scans: BMD and Trabecular Bone Score
It is challenging to diagnose osteopenia based on plain 
radiographs. Conventional X-ray films are insensitive to 
the changes in BMD. Patient might lose up to 50% of bone 
mass before it can be detected on a lumbar radiography 
[31]. Moreover, it is a subjective rather than objective tool 
with a significant interobserver variabilities. The agree-
ment between the readers for the diagnosis of osteopenia 






Although it is widely available and a good test for bone 
quantity, DEXA areal BMD does not detect the type of 
ROD in CKD patients and cannot evaluate bone quality. 
Other limitations of DEXA scans include the confound-
ing effects of surrounding soft tissue, bone artifacts caused 
by osteoarthritis, degenerated disks, vertebral compres-
sion fractures, and aortic calcification, which are not un-
common in CKD patients. However, femoral BMD is 
correlated with cortical porosity histomorphologically in 
dialysis patients [33]. Because DEXA is a 2-dimensional 
technique, it also cannot be used to measure true volu-
metric BMD (vBMD) and bone size or to separate tra-
becular from cortical bone. Thus, a large bone will yield a 
higher areal BMD than a small bone, although the vBMD 
would be the same.
Fractures occur in 30–50% of people with normal 
BMD. This might be due to lack of capturing of poor bone 
quality by DEXA scans. Trabecular bone score (TBS) cap-
tures vertebral trabecular texture from the lumbar DEXA 
images [34]. It is a noninvasive tool to assess bone micro-
architecture. TBS does not add any extra time, cost, or 
radiation exposure to the DEXA scans. The TBS software 
can be applied retrospectively to BMD images to better 
assess the bone quality and thus the fracture risk. TBS 
software has been modified over the past few years. TBS-
v1 algorithm was the initial software utilized to assess 
bone quality, which was developed after studies on fe-
males with average body habitus. The reference values 
could not correlate well in male population or people with 
a BMI of <15 or >35. TBS-v2 algorithm was developed to 
counter the shortcomings of the previous TBS version, 
and it has improved the fracture prediction [35].
Certain conditions like CKD, diabetes, obesity, and 
long-term glucocorticoid use have increased fracture risk 
despite normal BMD. All these conditions affect bone 
quality, particularly trabecular microarchitecture. TBS 
can be extremely helpful in predicting fracture risk and 
assessment of bone quality in these circumstances [36–
38]. TBS is usually low in patients with CKD including 
dialysis patients [39]. TBS correlated better with inci-
dence of fracture in pre-dialysis CKD, dialysis patients, 
and kidney transplant recipients, as compared to BMD 
[40, 41]. In a multivariate analysis in ESRD patients by 
Ramalho et al. [42], TBS was correlated with trabecular 
bone volume and trabecular width histopathologically. 
However, Holloway-Kew et al. [43] found that TBS and 
BMD did not correlate with prior history of fractures in 
CKD patients compared to micro-indentation parame-
ters.
Perez-Saez et al. [44] reported that despite a persistent 
decline in the BMD, TBS and bone quality stayed normal 
up to 10 years after kidney transplantation. Furthermore, 
Silva et al. [40] previously reported that TBS can be used 
as a tool to assess the response to different therapeutic 
interventions. They demonstrated a maximal TBS im-
provement with teriparatide followed by denosumab and 
tamoxifen, then bisphosphonates in older women.
Quantitative Ultrasound
Quantitative ultrasound (QUS) machines employ 
waves with lower frequencies compared to the conven-
tional soft tissue US. The studied skeletal sites are the dis-
tal metaphysis of the phalanx, the calcaneus, the radius, 
and the tibia. All these sites are predominantly cortical 
bone, except the calcaneus, which is mainly composed of 
trabecular bone [45].
As QUS waves propagate through the bone, their ve-
locity reflects the material properties of the bone such as 
its density, architecture, and elasticity. The degree of at-
tenuation of the wave amplitude, measured by broadband 
ultrasound attenuation, is influenced by trabecular sepa-
ration and other structural characteristics of trabecular 
bone. Several other more complex wave parameters such 
as shape (number of peaks), bone transmission time, and 
amplitude-dependent speed of sound (SOS) have been 
developed, and these have been correlated with several 
bone properties measured by micro-CT [46].
In the 1990s, studies on QUS showed that SOS mea-
sured in bones such as tibia inversely correlated with di-
alysis vintage and iPTH levels [47]. Similarly, in a study 
employing phalangeal QUS in HD patients, amplitude-
dependent SOS was significantly lower compared to con-
trol groups, and it was negatively correlated with iPTH 
levels [48]. Furthermore, HD patients had reduced calca-
neal broadband ultrasound attenuation and SOS scores 
compared to controls, and there was a significant asso-
ciation between calcaneal QUS parameters and DEXA 
scans [49]. QUS measures have been correlated with 
DEXA at both phalanges and calcaneus [50, 51]. In osteo-
porotic patients, QUS measurements have been used to 
monitor the effects of treatment with alendronate, ral-
oxifene, and teriparatide [45]. Ten-year fracture risk 
probabilities have been calculated using QUS measures in 
osteoporotic patients [52]. However, the predictive value 
for CKD patients has not been studied, and it is an inter-
esting potential topic for future research. It might also 
have an application in monitoring of therapy in ROD.





QCT is an in vivo diagnostic modality that can be ap-
plied to the axial or appendicular skeleton, where large 
body segments such as hip or spine are imaged to measure 
vBMD. One of the main advantages of QCT, particularly 
in CKD patients, is that it is not confounded by the pres-
ence of extra-osseous calcium, which can be a problem 
with DEXA scans. It also better identifies bone loss over 
time compared to DEXA in HD patients [53]. The disad-
vantages of this method include high radiation exposure 
and cost and it does not assess the type of ROD.
High-Resolution Peripheral Quantitative Computed 
Tomography
High-resolution peripheral quantitative computed 
tomography (HRpQCT) is another tool that employs 
narrower slice width and field of view compared to QCT 
and maximizes spatial resolution using image recon-
struction algorithms. It is a good tool to assess bone mi-
croarchitecture (cortical porosity and trabecular connec-
tivity) and vBMD at distal extremity sites such as distal 
radius and tibia. It provides more detailed information 
about bone microstructure than QCT, which does not 
detect trabecular thickness or cortical porosity [10]. 
Measurement of bone microarchitecture by HRpQCT in 
addition to BMD can explain the variance in bone 
strength. Studies using HRpQCT have demonstrated a 
preferential loss of cortical bone in CKD patients [16]. In 
CKD stages 2–4, before the onset of secondary hyper-
parathyroidism (SHPT), impairment of trabecular bone 
is noted with HRpQCT, and this could explain the in-
creased risk of fractures in early CKD. As CKD progress-
es and SHPT ensues, with increased turnover, bone loss 
assessed by HRpQCT is predominantly cortical and is 
highly associated with fractures in weight-bearing and 
non-weight-bearing sites [16, 54]. Measures of bone mi-
croarchitecture obtained by HRpQCT have been validat-
ed against bone micro-CT [55]. Nickolas et al. [15] in a 
cross-sectional study in pre-dialysis patients demon-
strated that several HRpQCT measures of microarchitec-
ture were significantly lower in patients with fractures. In 
CKD patients with HTBD and osteoporosis, there is can-
cellization of endocortical bone. This cancellization can 
confound cortical measurements obtained by HRpQCT 
and can lead to errors in quantifying changes in trabecu-
lar and cortical morphology [56].
High-Resolution Magnetic Resonance Imaging or 
Micro-Magnetic Resonance Imaging
High-resolution magnetic resonance imaging (HR-
MRI) or micro-MRI is a noninvasive and nonionizing 
method for the quantification of bone microarchitecture. 
Whereas HRpQCT is limited to places like ankle and 
wrist, HR-MRI can measure other sites like the proximal 
femur. In a small cross-sectional study in patients with 
ROD, MRI indices of trabecular network integrity corre-
lated with histomorphometric trabecular bone volume, 
separation, and thickness. HR-MRI parameters also cor-
related with trabecular separation measured by micro-CT 
and turnover indices [57]. Parameters of bone microar-
chitecture obtained by both HR-MRI and HRpQCT have 
been correlated with bone strength using finite element 
analysis (FEA) [58, 59].
Finite Element Analysis
FEA is a computational method that provides infor-
mation on bone quality, microarchitecture, fracture risk, 
and mechanical properties. It can be generated through 
QCT, HRpQCT, or MRI data. CT-based FEA improved 
assessment of bone strength compared to DXA or QCT 
but is not standardized, and variability in loading condi-
tions can affect the strength estimates [60, 61]. MRI-based 
FEA improved diagnosis precision, predicted fracture, 
and was useful for monitoring bone loss and response to 
treatment [61]. HRpQCT-based FEA cortical thickness 
and volume correlated with BTMs, while cortical poros-
ity correlated with PTH in a cross-sectional study in 
ESRD patients [62]. MRI-based micro-FEA mechanical 
parameters significantly decreased 6 months after kidney 
transplantation, but structural parameters did not change 
significantly by using micro-MRI only [59].
Reference Point Indentation
Reference point indentation (RPI) is a less invasive 
measure of bone material strength (BMS) compared to 
bone biopsy. The RPI instrument performs bone indenta-
tion testing by inserting a probe assembly through skin 
and subcutaneous tissues directly onto the surface of the 
bone after displacing the overlying periosteum in a very 
small area. Microscopic fractures are then induced on the 
surface of the bone, and bone mechanical properties at 





preclude the use of these methods. People on anticoagu-
lants need special attention to hemostasis [63]. Osteo-
probe is a newer version of RPI that measures bone mate-
rial properties by evaluating the BMS index without dis-
placing the periosteum or using a reference probe [64, 
65]. Patients with atypical femoral fractures have signifi-
cant abnormalities in BMS measurements using the RPI 
methods despite having normal DEXA-BMD scores [66].
Bone Biopsy and Histopathology
Bone biopsies are performed at the anterior iliac crest 
after double tetracycline labeling [67]. For diagnostic 
purposes, pathologists perform a qualitative comprehen-
sive assessment of the bone specimens [67, 68]. In addi-
tion, for research purposes, quantitative histomorpho-
metric analysis of bone sections may be used. Further-
more, bone quality and mechanical properties can be 
evaluated using various methods such as Fourier trans-
form infrared (FTIR) spectroscopy, FEA, and nano-, mi-
cro- and macro-indentation [69, 70].
In 2006, the Kidney Disease: Improving Global Out-
comes (KDIGO) introduced the notion that bone histo-
logical abnormalities in patients with CKD should be 
characterized by bone turnover, mineralization, and vol-
ume [71]. Bone turnover is classified as low, normal, or 
high. Mineralization is characterized as normal or abnor-
mal, and volume as low, normal, or high. The “abnormal” 
mineralization may include defective or precipitous dif-
fuse mineralization as in woven osteoid [72]. This classi-
fication should help the clinicians to focus on correcting 
the bone abnormalities observed in their patients and di-
rect appropriate therapies.
In patients with CKD stages 2–5 before dialysis, vari-
ous abnormalities have been described ranging from mild 
increase in bone turnover resulting from moderate SHPT, 
with or without mineralization defect [73–75], to various 
degrees of LTBD [76]. In an ongoing study, we found that 
the majority of adult patients with CKD stages 2–5 pre-
dialysis have low or low-normal bone turnover without 
mineralization defect. When patients reach ESRD, the 
bone abnormalities usually intensify. The spectrum of 
ROD histological features is very wide and has evolved 
over time. Traditionally, the various forms of ROD en-
compass predominant SHPT, adynamic bone disease, 
low turnover osteomalacia, and mixed uremic osteodys-
trophy. Predominant SHPT bone disease is characterized 
by HTBD with increased formation and resorption sur-
faces. Osteoid volume and surface are high with numer-
ous irregular osteoblasts and osteocytes. In some areas, 
osteoid and mineralized bone lose their normal lamellar 
structure and become irregularly “woven.” The resorp-
tion surfaces are high and resorption lacunae are deep 
with abundant multinucleated large osteoclasts. In addi-
tion, formation and resorption surfaces may be covered 
by peritrabecular fibrosis, which can extend deeply into 
the bone marrow. Under fluorescent light, the extent of 
tetracycline double labeling is high and may show diffuse 
uptake in woven osteoid. The cancellous bone volume/
tissue volume may be low, high, or normal, whereas cor-
tical bone exhibits a high degree of porosity.
At the other end of the spectrum, patients may present 
with adynamic bone disease, where bone turnover is very 
low with paucity of bone formation sites and osteoblasts. 
Osteoid volume and surface are low with thin osteoid 
seams. Osteoid and bone are mostly lamellar but may 
show some remnants of woven structure from previous 
overactivity. Similarly, bone resorption surfaces may vary 
from low to slightly elevated. Under fluorescent micros-
copy, the mineralizing surfaces are mainly low with few 
thin passive single labels. Cancellous bone volume and 
cortical thickness are usually low.
Low-turnover osteomalacia in CKD patients is charac-
terized by a severe mineralization defect with very high 
volume and surface of osteoid and wide osteoid seams. 
There is a paucity of osteoblasts. Resorption surfaces and 
osteoclasts may be seen on the few bone surfaces not cov-
ered with osteoid. The tetracycline uptake is minimal and 
consists of few thin single labels. This usually happens in 
patients with aluminum toxicity, where aluminum can be 
seen at the mineralization front. The cancellous bone vol-
ume and cortical thickness and porosity may vary from 
low to elevated.
Mixed ROD represents a combination of various de-
grees of SHPT along with signs of mineralization defect (os-
teomalacia). Bone volume and cortical thickness may vary.
The spectrum of bone diseases has evolved over the 
years [77]. In the early 1980s, there was a predominance 
of mixed ROD and low turnover osteomalacia (in the 
most severe cases) due to aluminum intoxication in ESRD 
patients. With prevention of aluminum toxicity in the 
subsequent years, the main histological forms of ROD 
consisted of various degrees of SHPT bone diseases. In 
the mid-1980s, the frequency of “aplastic” [78] or ady-
namic [79] bone disease increased significantly. More-
over, there are differences in the prevalence of the various 
histological forms of ROD between black and white pa-
tients with CKD. Black patients are less prone to develop 
LTBD and low bone volume [72, 73, 80–82].




In post-kidney transplant patients, several factors in-
fluence bone diseases such as pre-existing ROD, immu-
nosuppressive therapy, and suboptimal kidney function. 
One of the prominent effects of renal transplantation is 
bone loss [83] with low bone volume/tissue volume and 
decrease in bone turnover [84–86]. Focal or generalized 
mineralization defects are also not uncommon [85].
Bone histomorphometry is mainly used for research 
[87, 88]. The parameters that characterize bone turnover 
include bone formation rate/bone surface and activation 
frequency as well as number of osteoblasts and osteo-
clasts. Bone formation rate/bone surface relates exclu-
sively to the level of bone formation, whereas activation 
frequency includes also parameters of bone resorption 
and quiescent periods and indicates the frequency at 
which the bone is completely renewed. Defective miner-
alization is defined as osteoid thickness >20 μm and min-
eralization lag lime >100 days. Volume encompasses 
cancellous bone volume/tissue volume, trabecular thick-
ness, and separation as well as cortical thickness and po-
rosity. Normal values vary by age, gender [89, 90], and 
race.
FTIR Spectroscopy
FTIR provides another way to measure bone quality 
on bone biopsy specimens. The chemical bonds between 
the components of bone matrix and mineralized bone, 
like all chemical bonds, undergo vibrations. The param-
eters of FTIR spectroscopy pertinent to bone material 
properties that are measured include (a) mineral to ma-
trix ratio, (b) mineral maturity/degree of crystallization, 
(c) collagen cross-linking ratio (the relative proportion of 
mature to immature collagen), and (d) carbonate/phos-
phate ratio [91].
Malluche et al. [92] previously reported that mineral 
to matrix ratio is lower in dialysis patients with HTBD. 
This finding on FTIR in patients with HTBD correlated 
with lower hardness, as measured by nano-indentation 
techniques. There is shortened duration of remodeling 
cycle in HTBD, and this can lead to diminished duration 
of mineralization. This interferes with bone quality and 
leads to decreased bone stiffness [92]. In LTBD dialysis 
patients, there was no reduction in mineral to matrix ratio 
compared to normal controls. Hardness measured by na-
no-mechanical properties in this group was not de-
creased. However, the microstructural properties of bone, 
as measured by histomorphometry, such as trabecular 
volume and thickness were noted to be lower [92].
When combined with histological evaluation of the 
bone, FTIR can add valuable information on the bone 
material properties. As another example, changes in col-
lagen cross-link ratio strongly suggest that factors other 
than bone turnover may be playing a role in the clinically 
manifested fragility. FTIR technique is not widely avail-
able, and it needs human tissue from a bone biopsy. FTIR 
can only measure relative quantities of minerals and ma-
trix and the varying cross-link types and no absolute 
quantitation can be provided.
Micro-Computed Tomography
Micro-computed tomography is an ex vivo technique 
used to image small (millimeter-sized) bone samples us-
ing high amounts of radiation and can provide high-res-
olution 3D bone microstructural data [10]. It is not a clin-
ically available technique but is considered the gold stan-
dard for measurement of bone structure against which 
other in vivo modalities are usually compared [57]. Shar-
ma et al. [93] reported that micro-computed tomography 
was able to detect the deterioration of cortical microar-
chitecture in CKD patients. Of note, their cohort of pa-
tients did not have trabecular abnormalities.
Conclusion
CKD-induced bone quality and quantity abnormali-
ties are complex disorders that confer high morbidity and 
mortality in the CKD population. Proper diagnosis of the 
actual underlying skeletal problems helps to prevent fu-
ture bone loss and fractures. Once the diagnosis of ROD 
has been established, knowing the bone quality and turn-
over abnormality could help predict the fracture risk.
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